Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GONB vs Medical Treatment in Chronic Migraine
NCT06122545Unknown
- Sponsor
- Tanta University
- Start
- May 2022
- Primary completion
- May 2024
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of botulinum toxin type A and bupivacaine in chronic migraine, sponsored by Tanta University. Primary endpoint: Severity of headache at 3 months. Status: unknown.
02
Drugs
botulinum toxin type Abupivacaine
03
Conditions
chronic migraine
Beyond the preview
Go deeper on NCT06122545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06122545.